Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ALPRAZOLAM ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ALPRAZOLAM ORALLY DISINTEGRATING TABLETS. ALPRAZOLAM orally disintegrating tablets, C-IVInitial U.S. Approval: 2005
Medication labelWhy this: Advisory · dailymed-prescription
Alprazolam orally disintegrating tablets, USP are indicated for the treatment of generalized anxiety disorder. The efficacy of alprazolam in the treatment of generalized anxiety disorder was demonstrated in 5 short-term, placebo-controlled trials [see Clinical Studies (14.1)]. Alprazolam orally disintegrating tablets, USP are also indicated for the treatment of panic disorder, with or without agoraphobia. The efficacy of alprazolam in the treatment of panic disorder was established in 2 short-term, placebo-controlled trials [see Clinical Studies (14.2)]. Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months in duration for generalized anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient.
- generic_name
- alprazolam
- product_names
- alprazolam
- ndc
- 49884-110, 49884-110-74, 49884-111, 49884-111-74, 49884-213, 49884-213-74, 49884-214, 49884-214-74
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en